Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial - Garassino, M C; Martelli, O; Broggini, M (Lancet Oncol, 2013)
, et al; TAILOR trialists.